Navigation Links
BioSyntech to conclude enrolment for pivotal BST-CarGel(R) trial in February 2009
Date:1/14/2009

ch statements are subject to a multitude of risks and uncertainties that could cause actual results, future circumstances, or events to differ materially from those projected in the forward-looking information. These risks include, but are not limited to, those associated with our capacity to finance our activities, the adequacy, timing, and results of our clinical trials, the regulatory approval process, competition, securing and maintaining corporate alliances, market acceptance of the Company's products, the availability of government and insurance reimbursements for the Company's products, the strength of intellectual property, the success of research and development programs, reliance on subcontractors and key personnel, and other risks and uncertainties detailed from time-to-time in our filings with the Canadian securities commissions.

Readers should not place undue reliance on the forward-looking information, given that (i) our actual results could differ materially from a conclusion, forecast or projection in the forward-looking information, and (ii) certain material factors or assumptions which were applied in drawing a conclusion or making a forecast or projection as reflected in the forward-looking information, could prove to be inaccurate. Additional information about (i) the material factors that could cause actual results to differ materially from the conclusion, forecast or projection in the forward-looking information, and (ii) the material factors or assumptions that were applied in drawing a conclusion or making a forecast or projection as reflected in the forward-looking information, is contained in the Company's annual report and other documents filed from time to time with the Canadian securities commissions which are available at www.sedar.com. These statements speak only as of the date they are made, and we assume no obligation to revise such statements as a result of any event, circumst
'/>"/>

SOURCE BioSyntech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cephalon Concludes All Outstanding Federal and State Government Investigations into the Companys Sales and Promotional Practices
2. Exelixis and GlaxoSmithKline Agree to Successfully Conclude Six-Year Discovery and Development Collaboration
3. West Concludes Agreement with Nektar
4. Workforce Alliance Concludes Three-Year Biotech Training Program
5. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
6. Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R)
7. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
8. Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment
9. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. Oncolytics Biotech Inc. Proceeds to Full Enrolment in U.S. Phase II Sarcoma Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Sept. 18, 2014 Research and Markets ... Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market ... their offering. The global companion diagnostics ... 22.7% from 2014 to 2019. Factors such as rising ... of companion diagnostics by the pharmaceutical industry, support from ...
(Date:9/18/2014)... 18, 2014  U.S. biotech company Kultevat ... license for technology developed by the Donald Danforth ... plants, including for applications in production of natural rubber ... technology was developed under the direction of Roger ... former president of the Danforth Plant Science Center, and ...
(Date:9/18/2014)... 18, 2014  Neogen Corporation (Nasdaq: NEOG ... strategic agreement with Merck Animal Health to market Neogen,s ... The Igenity Dairy Heifer Program consists of genomic tests ... genetic potential of replacement dairy heifers. The genomic tests ... and is an excellent tool in the decision-making process ...
(Date:9/18/2014)... 18 septembre 2014 Mapi, société créée ... 1974, a été depuis 40 ans l,un ... cliniques traditionnelles par des évaluations recentrées sur ... les impacts économiques des traitements. ... A cours d,une récente conférence téléphonique ...
Breaking Biology Technology:Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Kultevat obtains license of gene switch technology 2Merck Animal Health to market Neogen's dairy genomic program 21974 - 2014 - Mapi fĂȘte ses 40 ans 2
... Martek Biosciences Corporation (Nasdaq: MATK ) announced ... Needham Life Sciences Conference which is scheduled to take place ... New York City. Peter L. Buzy, Chief Financial Officer, ... 2:30 p.m. Eastern Time.A live audio webcast of Martek,s presentation ...
... the presenters at Digestive Disease Week, addressing the topic ... May 29 Zeus, Inc., a leader in polymer ... to present at Digestive Disease Week in Chicago on ... and GI Endoscopy Specialist Aubrey Sanders will address possible ...
... May 29 The Gerresheimer,Group today opened ... in China.,The high-tech production facility constructed in ... in high-quality pharmaceutical,vials and cartridges for injection ... industry on both a local and international ...
Cached Biology Technology:Zeus to Present at Digestive Disease Week in Chicago 2Gerresheimer Opens New High-Tech Production Facility for Pharma Glass in China 2Gerresheimer Opens New High-Tech Production Facility for Pharma Glass in China 3
(Date:9/18/2014)... to acquire and creatively manipulate spoken language is unique ... past 6 million years of human evolution to make ... best candidate gene we now have," says Wolfgang Enard, ... his efforts to understand the molecular biological basis of ... The results of his latest study, undertaken in collaboration ...
(Date:9/18/2014)... CHANDLER, AZ, Sept. 18, 2014 -- Arizona turned its ... in just a few short months, earning it the first-ever ... , The March of Dimes presented Will Humble, M.P.H., Arizona,s ... ceremony held here today. Mr. Humble established a policy of ... hospitals to send newborn blood samples to the lab for ...
(Date:9/18/2014)... Eight researchers from several disciplines will be celebrated tonight ... their roles in improving the health of premature infants ... supercomputing revolutions. The researchers, whose work was supported by ... and the former Atomic Energy Commission, will be honored ... Washington, DC. A bipartisan group of Members of Congress ...
Breaking Biology News(10 mins):Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 33rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2
... from the Walter and Eliza Hall Institute have overturned ... is controlled, solving the structure of a protein that ... be a potential drug target for future malaria and ... factor 1 (ADF1), a key protein involved in controlling ...
... Laboratory research has always been limited in terms of what ... human population as a whole. Many promising findings in ... because laboratory animals, bred from a limited genetic foundation, don,t ... the broader human population. Now, thanks to ...
... as they age, according to a new study at ... and behavioral measures to understand how the brain responds ... adults distinguish between damage done either intentionally or accidently ... Nonetheless, adults are much less likely than children to ...
Cached Biology News:New malaria protein structure upends theory of how cells grow and move 2New malaria protein structure upends theory of how cells grow and move 3Of mice and men: UNC-led team solves mouse genome dilemma 2Changes in brain circuitry play role in moral sensitivity as people grow up 2Changes in brain circuitry play role in moral sensitivity as people grow up 3
Request Info...
R26.4C...
... x H): 17 3/4" x 8 ... slidesTime: Programmable 0 - 100 hoursControl: Programmable ... steps 40 user programmable protocols 3 operating ... Rapid temperature ramp-up from 37 - 95C ...
Anti-DAP-1, Rabbit Monoclonal Immunogen: KLH-conjugated synthetic peptide corresponding to the C-terminal region of human DAP-1. Molecular Weight: 11 kDa Quality Assurance: Routinely eval...
Biology Products: